Ana Claudia Latronico watches children walk into her clinic at the University of São Paulo, some visibly distressed by changes their bodies have started too soon. Now, thanks to new guidance she helped shape, doctors like her have a roadmap to spare them unnecessary poking, prodding, and treatment. The Endocrine Society released a groundbreaking clinical practice guideline on Saturday at ENDO 2026 that fundamentally shifts how physicians approach early puberty—moving away from a one-size-fits-all protocol toward careful, individualized care.
Central precocious puberty happens when a child's brain activates puberty-related hormones too early: before age 8 in girls, before age 9 in boys. The physical changes that follow—breast development in girls, testicular enlargement in boys, rapid growth—can arrive with painful emotional weight. For decades, doctors reflexively ordered extensive tests and treatments. But emerging evidence now shows that not all children with early puberty need the same intervention, and some may not need treatment at all.
The stakes are real. Early puberty can affect a child's adult height and carries long-term health risks, including psychosocial stress, heart disease, and some cancers later in life. Yet the new guideline, published in The Journal of Clinical Endocrinology & Metabolism, moves clinicians toward restraint and observation before jumping to intervention.
Take the example Dr. Stephanie Roberts, co-chair of the guideline committee at Boston Children's Hospital, highlights: older girls with slowly progressing precocious puberty often achieve normal adult height without any treatment whatsoever. This simple fact upends conventional practice. Instead of immediate testing, the guideline suggests monitoring girls with early breast development through physical exams every 4 to 6 months. For girls under 7, doctors can observe for 4 to 6 months to determine whether puberty is advancing slowly or rapidly—a distinction that fundamentally changes the clinical picture.
When testing is warranted, the guideline champions simplicity over invasiveness. A basal luteinizing hormone (LH) blood test becomes the first-line tool, replacing more burdensome GnRH agonist stimulation testing. Routine brain MRIs—a standard in older practice—are now reserved for children with actual neurological symptoms, not ordered on schedule. Genetic testing is discouraged unless early puberty runs in the family. When puberty-pausing medication is used, longer-acting formulations are preferred for long-term therapy. Growth hormone therapy is not routinely recommended. And lab monitoring during treatment becomes selective, ordered only when doctors suspect treatment failure.
"Children who start puberty earlier than usual should be carefully evaluated so they receive the right care at the right time—without unnecessary tests or treatment," Latronico said. The philosophy embedded in these nine recommendations represents a mature medical approach: knowing when to act, when to wait, and when to simplify.
By early adolescence—around ages 10 to 11 for girls, 11 to 12 for boys—therapy is typically discontinued. What emerges from these guidelines is a portrait of pediatric medicine becoming less reflexive and more thoughtful, driven by what actually helps children, not by protocol inertia. For families navigating the confusion and worry of early puberty, that shift offers something precious: the promise of care calibrated to their child's actual needs.